Advertisements


What"s Ahead For Axsome Therapeutics?

What"s Ahead For Axsome Therapeutics?.....»»

Category: topSource: seekingalphaJan 12th, 2019

Axsome Therapeutics: Still 5 Catalysts Ahead In 2019

Axsome Therapeutics: Still 5 Catalysts Ahead In 2019.....»»

Category: topSource: seekingalphaJan 7th, 2019

What"s Ahead For Axsome Therapeutics

What"s Ahead For Axsome Therapeutics.....»»

Category: topSource: seekingalphaDec 12th, 2018

Axsome Therapeutics price target raised to $18 from $15 at H.C. Wainwright

See the rest of the story here. Theflyonthewall.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fl.....»»

Category: blogSource: theflyonthewallMar 15th, 2019

Axsome Therapeutics price target raised to $16 from $13 at Cantor Fitzgerald

See the rest of the story here. Theflyonthewall.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fl.....»»

Category: blogSource: theflyonthewallMar 15th, 2019

Axsome Therapeutics (AXSM) CEO Herriot Tabuteau on Q4 2018 Results - Earnings Call Transcript

Axsome Therapeutics (AXSM) CEO Herriot Tabuteau on Q4 2018 Results - Earnings Call Transcript.....»»

Category: topSource: seekingalphaMar 14th, 2019

Axsome Therapeutics, Inc. 2018 Q4 - Results - Earnings Call Slides

Axsome Therapeutics, Inc. 2018 Q4 - Results - Earnings Call Slides.....»»

Category: topSource: seekingalphaMar 14th, 2019

Axsome Therapeutics Reports Fourth Quarter and Full Year 2018 Financial Results and Provides Business Update

Company to host conference call today at 8:00 AM Eastern NEW YORK, March 14, 2019 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ:AXSM), a clinical-stage biopharmaceutical company developin.....»»

Category: earningsSource: benzingaMar 14th, 2019

Axsome Therapeutics reports Q4 EPS (32c), consensus (30c)

See the rest of the story here. Theflyonthewall.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fl.....»»

Category: blogSource: theflyonthewallMar 14th, 2019

Cara Therapeutics (CARA) Reports Q4 Loss, Tops Revenue Estimates

Cara (CARA) delivered earnings and revenue surprises of 11.86% and 65.26%, respectively, for the quarter ended December 2018. Do the numbers hold clues to what lies ahead for the stock? Want the latest recommendations from Zacks .....»»

Category: personnelSource: nytMar 12th, 2019

Analysts Positive On Insys Ahead Of 2019 Pipeline Catalysts

Insys Therapeutics Inc (NASDAQ: INSY), which specializes in painkillers and synthetic cannabinoid drugs, reported Thursday after the close with a sharp decline in revenue and .....»»

Category: earningsSource: benzingaMar 8th, 2019

Analysts Positive On Insys Ahead Of 2019 Pipeline Catalysts

Insys Therapeutics Inc (NASDAQ: INSY), which specializes in painkillers and¬†synthetic cannabinoid drugs, reported Thursday after the close with a¬†sharp decline in reve Latest Ratings for .....»»

Category: blogSource: benzingaMar 8th, 2019

The Biotech Stock Rally May Just Be Getting Started

Big biotech ETF holdings such as Sage Therapeutics, Celgene, and bluebird bio are running well ahead of the market so far this year, and that could force investors to chase other biotech stocks......»»

Category: topSource: barronsFeb 13th, 2019

JMP upgrades Proteon Therapeutics to Outperform ahead of phase 3 data readout

See the rest of the story here. Theflyonthewall.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fl.....»»

Category: blogSource: theflyonthewallFeb 11th, 2019

Global Blood Therapeutics: A Crucial Year Ahead

Global Blood Therapeutics: A Crucial Year Ahead.....»»

Category: topSource: seekingalphaFeb 8th, 2019

Axsome Therapeutics reaches agreement under SPA for MOMENTUM Phase 3 trial

See the rest of the story here. Theflyonthewall.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fl.....»»

Category: blogSource: theflyonthewallFeb 6th, 2019

Axsome Therapeutics call volume above normal and directionally bullish

See the rest of the story here. Theflyonthewall.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fl.....»»

Category: blogSource: theflyonthewallFeb 1st, 2019

Axsome Therapeutics initiates CONCERT study

See the rest of the story here. Theflyonthewall.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fl.....»»

Category: blogSource: theflyonthewallJan 30th, 2019

3 Small-Cap Stocks With Big-Cap Potential

Sierra Wireless, Innovative Industrial Properties, and Axsome Therapeutics could generate multibagger returns over the long term......»»

Category: topSource: moneycentralJan 16th, 2019

Bank Of America Takes Neutral Stance On Cara Therapeutics Ahead Of Phase 3 Korsuva Results

Cara Therapeutics Inc (NASDAQ: CARA) got some love from Wall Street on Tuesday, with one analyst projecting significant upside for the stock based the outlook for its leading drug candidate. Latest Ratings for CARA DateF.....»»

Category: blogSource: benzingaJan 15th, 2019

BofA Takes Neutral Stance On Cara Therapeutics Ahead Of Phase 3 Korsuva Results

Cara Therapeutics Inc (NASDAQ: CARA) got some love from Wall Street on Tuesday, with one analyst projecting significant upside for the stock based the outlook for its leading drug candidate. Latest Ratings for CARA DateF.....»»

Category: blogSource: benzingaJan 15th, 2019